Voriconazole Cas 137234-62-9 Triazole Antifungal Drugs

Voriconazole is a triazole antifungal medication that is generally used to treat serious, invasive fungal infections. Voriconazole has also been proven effective against a number of other serious fungal pathogens. This includes infections by Fusarium spp and Scedosporium apiospermum (asexual form of Pseudallescheria boydii). Although infrequently seen, these molds are emerging as more common and deadly causes of fungal infection in seriously immunocompromised patients, and the development of voriconazole has been an important advance in their treatment as they are generally resistant to other antifungal agents (including amphotericin B). Voriconazole is the first and only drug ever specifically indicated for their treatment by the FDA. Voriconazole has also been used to treat severe fungal corneal infection.

Properties

Appearance & Physical State: white to off white crystalline powder

Density: 1.42 g/cm3

Boiling Point: 508.6ºC at 760 mmHg

Melting Point: 127-130ºC

Flash Point: 261.4ºC

Refractive Index: 1.616

Vapor Pressure: 3.63E-11mmHg at 25°C

P450 (e.g. CYP17) inhibitor Related Products:

Abiraterone; Abiraterone acetate; Ketoconazole; Orteronel(racemic); Orteronel; Galeterone; Cobicistat; Ozagrel; Ritonavir; Posaconazole; Fluconazole; Clarithromycin

[1]. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 2011 Jun;12(6):861-72. doi: 10.2217/pgs.11.18.

[2]. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x.